MDxHealth S.A.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MDXH research report →
Range $2 – $3
Price Chart
About the company
MDxHealth SA is a commercial-stage precision diagnostics firm delivering specialized urologic solutions across the globe. Its international footprint includes the United States, various European nations such as the Netherlands, Belgium, Spain, Poland, Italy, and the wider European Union. The company's innovative genomic testing portfolio for prostate cancer comprises SelectMDx, a non-invasive urine test, and ConfirmMDx, an epigenetic diagnostic tool.
- CEO
- Michael K. McGarrity
- IPO
- 2021
- Employees
- 364
- HQ
- Herstal, WA, BE
Get TickerSpark's AI analysis on MDXH
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $10.25M
- P/E
- -0.10
- PEG
- 0.01
- P/S
- 0.08
- P/B
- -0.33
- EV/EBITDA
- -4.75
- Div Yield
- 0.00%
- Gross Margin
- 59.13%
- Op Margin
- -25.86%
- Net Margin
- -46.30%
- ROE
- 257.40%
- ROIC
- -32.19%
Latest fiscal year · YoY change
- Revenue
- $107.88M+19.8%
- Gross Profit
- $64.44M+16.9%
- Op Income
- $-15,401,000
- Net Income
- $-33,519,000+12.0%
- EPS
- $-0.67+14.1%
- OCF Growth
- +43.8%
- FCF Growth
- +44.1%
- 52W High
- $4.34
- 52W Low
- $0.10
- 50D MA
- $0.38
- 200D MA
- $1.26
- Beta
- 0.39
- RSI (14)
- 22
- Avg Volume
- 933.07K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
MDxHealth reported flat Q3 revenue but weaker profitability as commercial turnover disrupted execution, and management is resetting the sales organization for a hoped-for return to growth in 2027.· November 12, 2026
- Q3 revenue from continuing operations was $22.7 million, flat year over year, but gross margin fell to 61.8% from 65%.
- Operating loss widened to $8.1 million and adjusted EBITDA was negative $6.3 million as ExoDx-related costs and headcount weighed on results.
- Management said the quarter was hurt by accelerated sales-force turnover after the Resolve UTI wind-down, prompting a commercial restructuring and elimination of the Chief Commercial Officer role.
- The company expects to exit Q4 with a fully staffed sales organization and sees a linear recovery through 2027, but it is not providing formal guidance yet.
- Cash and cash equivalents were $31.7 million at September 30, 2026, and management said it does not see a material unfavorable change in the cost structure ahead.
Revenue from continuing operations for Q3 2026 was $22.7 million, flat versus Q3 2025. Gross profit was $14 million versus $14.8 million a year ago, and gross margin was 61.8% compared with 65% in Q3 2025, a decline of 3.2 percentage points. Operating expenses increased 16% to $22.2 million, producing an operating loss of $8.1 million versus $4.4 million last year. Net loss from continuing operations was $12.3 million, up 26% from $9.7 million, and adjusted EBITDA was negative $6.3 million versus negative $0.9 million. Cash and cash equivalents were $31.7 million at September 30, 2026. Management did not provide numeric quarterly or full-year guidance, but said it expects Q3 and Q4 to run about in line with each other and characterized Q3 as the nadir, with recovery beginning in Q1 through Q4 of 2027. It also said it expects to exit Q4 with a fully staffed sales organization and return to growth in 2027.
CEO Michael McGarrity framed the quarter as a commercial execution issue rather than a demand problem, saying the disruption came from accelerated sales turnover after discontinuing Resolve. He said the company is resetting the commercial organization by splitting sales and marketing into separate groups reporting directly to him, with the goal of tighter accountability and better customer focus. His tone was confident and corrective, emphasizing that MDxHealth remains a growth company focused on urologic cancers and is positioned for 2027 catalysts including ProMPT data, the ProtecT trial, and AI initiatives.
Interim CFO Ron Kalfus detailed the quarter’s financial pressure points: revenue of $22.7 million, gross profit of $14 million, gross margin of 61.8%, operating expenses of $22.2 million, operating loss of $8.1 million, net loss of $12.3 million, and adjusted EBITDA of negative $6.3 million. He attributed the lower margin and higher losses mainly to the mix shift toward liquid testing and the expanded footprint, headcount, and operating expenses tied to ExoDx. He also reported $31.7 million in cash and cash equivalents and noted that all Q3 and prior-year figures discussed were for continuing core operations only, with Resolve reclassified as a discontinued operation.
Analysts pressed management on whether Q3 was the low point, how long the new reps will take to ramp, and whether the company can still reach its growth goals. McGarrity said Q3 was likely the nadir, Q4 should be roughly in line with Q3, and the recovery should start in 2027 with a linear acceleration through the year; he also said the rep ramp should take about one to two quarters. On cash, he said the company does not see a material unfavorable change in cost structure and does not expect material additional outlay for the ProtecT study. He also said the commercial reset and hiring have not hurt recruiting quality, and that the market opportunity in GPS, especially active surveillance, remains intact despite competitive volatility.
Management believes the commercial reset will restore execution and that the company can exit Q4 with a fully staffed sales force. It also pointed to multiple 2027 catalysts, including ProtecT, ProMPT data, and AI initiatives that could add value across operations and products. CEO confidence was reinforced by repeated claims that the underlying demand, customer relationships, and long-term market opportunity remain unchanged.
The quarter showed clear pressure: flat revenue, lower gross margin, wider operating losses, and negative adjusted EBITDA. Management acknowledged that sales execution was disrupted by accelerated turnover and that Q4 is unlikely to show an immediate turnaround, while also declining to give numerical guidance. Cash was $31.7 million, and investors raised concern about cash burn, restructuring costs, and funding upcoming initiatives even though management said it does not expect a material cost-structure hit.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 80.9%
- Shares Outstanding
- 95.42M
- Float Shares
- 77.22M
of shares held by institutions
26 13F filers
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Bleichroeder LP | 31.03M | ▲ 23.66M |
| Mvm Partners, LLC | 6.65M | ▲ 1.95M |
| Awm Investment Company, Inc. | 3.96M | ▲ 3.96M |
| Perkins Capital Management Inc | 1.29M | ▼ 124.97K |
| Gsa Capital Partners Llp | 593.35K | ▲ 111.36K |
| Jane Street Group, LLC | 299.30K | ▼ 203.92K |
| Citadel Advisors LLC | 262.53K | ▼ 247.15K |
| Renaissance Technologies LLC | 224.98K | ▼ 100.10K |
| Blackrock, Inc. | 143.01K | ▼ 4.05K |
| Millennium Management LLC | 119.97K | ▼ 108.54K |
| Two Sigma Securities, LLC | 26.51K | ▲ 26.51K |
| Lido Advisors, LLC | 24.27K | ▲ 4.01K |
Held by 2 ETFs
Biggest fund positions in MDXH by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 13, 26 | MVM Partners, LLC | buy | 2,202,643 |
| May 18, 26 | OConnell Brendan | other | 0 |
| Mar 18, 26 | Bednarski Eric | other | 0 |
| Mar 18, 26 | Bellano John | other | 0 |
| Mar 18, 26 | Bellano John | other | 0 |
| Mar 18, 26 | Bellano John | other | 0 |
| Mar 18, 26 | Bellano John | other | 0 |
| Mar 18, 26 | Bellano John | other | 0 |
| Mar 18, 26 | Bellano John | other | 0 |
| Mar 18, 26 | Bellano John | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our MDXH coverage
Recent articles, reports, and earnings notes.
No research on MDXH yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate MDXH report →MDxHealth SA (MDXH) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 12
MDxHealth SA (MDXH) Reports Q3 Loss, Misses Revenue Estimates
zacks.com · Nov 12
Mdxhealth Reports Third Quarter 2026 Financial Results
globenewswire.com · Nov 12
Geron (NASDAQ:GERN) & MDxHealth (NASDAQ:MDXH) Critical Review
defenseworld.net · Nov 6
Mdxhealth to Release Third Quarter 2026 Financial Results on November 12
globenewswire.com · Oct 29
MDxHealth Announces Preliminary Third Quarter 2026 Revenue and Suspends Full-Year 2026 Revenue Guidance
globenewswire.com · Oct 15
Comparing MDxHealth (NASDAQ:MDXH) & Shattuck Labs (NASDAQ:STTK)
defenseworld.net · Oct 2
MDxHealth Says Well-Positioned to 'Return to Positive EBITDA'
benzinga.com · Aug 14
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.